A Phase Ib/II Study of APG-1252 as a Single Agent or in Combination With Other Therapeutic Agent in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma(NHL)
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Palcitoclax (Primary) ; Tucidinostat (Primary)
- Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 15 Aug 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2026.
- 15 Aug 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2025.
- 27 Jul 2022 Status changed from not yet recruiting to recruiting.